Occasionally, pharmaceutical companies mark down the price of a new drug sold to pharmacies during a trial phase, when the drug is being marketed to buyers. Such trials often cause pharmacies to buy a huge amount of the drug. Nonetheless, the pharmaceutical companies could often profit more by not giving trials.
Which of the following, if true, most strongly supports the claim above about the pharmaceutical companies’ profits?
A. Generally, the quantity of markdown given by pharmaceutical companies to pharmacies is prudently calculated to be the least needed to attract buyers to the drug.
B. For many drugs, the trial phase during which prices are lowered is about a month, which is not long enough for buyers to get used to the low price.
C. The rationale of such trials is to keep the new drugs at the top of buyers’ minds and appeal to buyers now using competing drugs.
D. Pharmacies often amass in their storage rooms drugs bought at markdown during trials and then sell these drugs later at regular prices.
E. If some pharmaceutical companies offer trials but other competing pharmaceutical companies do not, the companies that offer trials will lure buyers away from the other companies.